In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Standard BioTools Inc (NASDAQ: LAB) was $1.2 for the day, up 4.35% from the previous closing price of $1.15. In other words, the price has increased by $4.35 from its previous closing price. On the day, 1.57 million shares were traded. LAB stock price reached its highest trading level at $1.25 during the session, while it also had its lowest trading level at $1.13.
Ratios:
Our analysis of LAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 16, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $3.50.TD Cowen initiated its Buy rating on April 16, 2024, with a $3.50 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 09 ’25 when Casdin Partners Master Fund, L bought 100,000 shares for $1.29 per share. The transaction valued at 128,920 led to the insider holds 60,875,000 shares of the business.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $319,350 on Sep 04 ’25. The Director now owns 60,775,000 shares after completing the transaction at $1.28 per share. On Sep 03 ’25, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 250,000 shares for $1.27 each. As a result, the insider paid 316,400 and bolstered with 60,525,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 458394144 and an Enterprise Value of 175179392. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.97 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 1.017 whereas that against EBITDA is -1.438.
Stock Price History:
The Beta on a monthly basis for LAB is 1.24, which has changed by -0.4285714 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.32, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is -8.17%, while the 200-Day Moving Average is calculated to be -4.04%.
Shares Statistics:
LAB traded an average of 1.34M shares per day over the past three months and 1569590 shares per day over the past ten days. A total of 381.69M shares are outstanding, with a floating share count of 365.52M. Insiders hold about 4.31% of the company’s shares, while institutions hold 73.95% stake in the company. Shares short for LAB as of 1760486400 were 11839646 with a Short Ratio of 8.82, compared to 1757894400 on 11992813. Therefore, it implies a Short% of Shares Outstanding of 11839646 and a Short% of Float of 4.8600003.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Standard BioTools Inc (LAB) in the stock market.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.09 and -$0.09 for the fiscal current year, implying an average EPS of -$0.09. EPS for the following year is -$0.04, with 1.0 analysts recommending between -$0.04 and -$0.04.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 3 analysts. It ranges from a high estimate of $18.3M to a low estimate of $17.7M. As of . The current estimate, Standard BioTools Inc’s year-ago sales were $44.97MFor the next quarter, 3 analysts are estimating revenue of $19.3M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $18.4M.
A total of 3 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $100.4M, while the lowest revenue estimate was $78M, resulting in an average revenue estimate of $86.37M. In the same quarter a year ago, actual revenue was $174.43MBased on 3 analysts’ estimates, the company’s revenue will be $79.73M in the next fiscal year. The high estimate is $81M and the low estimate is $78.7M.
